EP Mediate Co.,Ltd. provides non-clinical (in vivo and in vitro) functional and safety evaluations, identification of active ingredients, and studies on qualitative and quantitative analytical methods. This section introduces the features of EP MEDIATE’s non-clinical studies, examples of disease models, and related case studies. Please use this information as a reference when selecting a contract research organization (CRO) for non-clinical studies.
Since 2001, EP Mediate Co.,Ltd. has specialized in the development of health and functional foods as a food-focused CRO, accumulating extensive experience in this field. The company has conducted over 1,600 commissioned clinical trials (human studies) and approximately 800 non-clinical studies. It has worked with about 500 client companies, including overseas partners, and has established a nationwide network of medical institutions and study participants across Japan.
This network enables the evaluation of effects on humans for a wide range of products, including foods, supplements, health foods, cosmetics, exercise devices, beauty equipment, and relaxation products.
Reference: EP Mediate Co.,Ltd. official website ( https://www.ep-mediate.co.jp/business_ffc.php#01 )
EP Mediate Co.,Ltd. provides diverse contract research services, including clinical trials (human studies) for food products, basic and animal research, and studies on functional ingredients.
With renowned experts in medicine and statistics as advisors, we provide sophisticated and precise services. Also, consulting and assistance with thesis development,Total R&D supportIt is a system that can
ITEC Labs conducts contract research that integrates genomics and molecular analysis, monkey model studies, in vivo efficacy and functional studies using small animals and cells, metabolomics analysis, and gut microbiota profiling.
The company conducts a wide range of safety tests, including single and repeated dose toxicity tests, genotoxicity tests (Ames, chromosomal aberration, micronucleus), reproductive and developmental toxicity tests, carcinogenicity tests, and skin and eye irritation tests.
Efficacy studies are conducted using various animal disease models to evaluate blood pressure reduction, blood glucose control, body fat reduction, arthritis relief, cholesterol reduction, anti-allergy effects, anti-tumor effects, and improvement of hyperuricemia.
EP MEDIATE can accommodate specialized testing requests, including safety evaluations of cosmetics and topical agents, in vitro tests, efficacy screening using genetic analysis, special analyses, and repellency tests.
EP MEDIATE is engaged in medical device development support, health food development support (food CRO), and in vitro diagnostic (IVD) development support businesses.
| Address | 1-8 Tsukudo-cho, Shinjuku-ku, Tokyo |
|---|---|
| Tel | Not listed |
| Website | https://www.ep-mediate.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.